Return to NIEHS | Current Issue
Increase text size Decrease text size

Nobel Winner Speaks at RNA Society Meeting

By Dixie Ann Sawin
November 2009

Ada Yonath, Ph.D.
Shown during an interview at the N.C. Biotechnology Center, Yonath was animated as she described her life in science. She said her prize-winning research started with the question, "How do ribosomes translate the genetic code and make proteins?"
(Photo courtesy of Steve McCaw)

Kevin
When he first agreed to chair the session featuring Yonath, UNC chemist Kevin Weeks, Ph.D., didn't know he would be introducing a Nobel Prize winner. (Photo courtesy of Steve McCaw)

Yonath spoke to a capacity audience in the auditorium at the N.C. Biotechnology Center.
Yonath spoke to a capacity audience in the auditorium at the N.C. Biotechnology Center. (Photo courtesy of Steve McCaw)

Sponsored in part by NIEHS, the "Symposium on RNA Biology VIII: RNA Tool and Target" was held on October 16 and 17 at the North Carolina Biotechnology Center in the RTP. One of the highlights of the program was the talk given by the recent winner of the Nobel Prize in Chemistry, Ada Yonath, Ph.D., of the Weizmann Institute of Science, Israel. Her seminar offered insights into "The identification of the prebiotic translation apparatus within the contemporary ribosome."

The symposium was organized by the RNA Society of North Carolina. (http://www.med.unc.edu/pmbb/nc-rna-soc.html)Exit NIEHS NIEHS Principal Investigator Traci Hall, Ph.D., was co-chair of the event's organizing committee.

Ribosomes, which exist in eukaryotic and prokaryotic organisms, are the "cellular machines" that translate RNA into protein. However, eukaryotic and prokaryotic ribosomes exhibit several differences. In eukaryotic organisms, ribosomes exist either as free structures in the cytosol or bound to the endoplasmic reticulum (ER), a membrane-bound compartment within the cytoplasm.

Generally, proteins that are produced by the free ribosomes will function within the cell, while the proteins formed by ER-bound ribosomes will be exported from the cell. Eurkaryotic ribosomes usually number in the millions and are larger compared to their prokaryotic counterparts. In contrast, ribosomes from prokaryotic sources, such as bacteria and viruses, occur only as free-standing organelles and may number in the thousands.

Yonath began her talk by showing a movie depicting the motions of the ribosome that guide the entrance and exit of tRNAs from a specific tunnel within the active site of the ribosome, the peptidyl transferase center (PTC). The PTC resides in an internal architectural unit within a highly conserved symmetrical region that facilitates the ribosome's primary catalytic function of peptide bond formation and amino acid polymerization. Ribosomes can make 15-20 peptide bonds per second, with an accuracy rate of 99.99 percent.

Although differences exist between prokaryotes and eukaryotes, the universality of the symmetrical design and high conservation implies that this structure can transcend different environmental conditions and is most likely the remnant of the ancient protein biosynthetic machine, the proto-ribosome, akin to a "molecular fossil." As Yonath explained, "The chemical prebiotic process originated from an oligonucleotide... that proceeded into self-assembled dimers." Thus, small pieces of RNA could spontaneously dimerize and form the building block for the protoribosome, the pre-protoribosome.

This internal symmetry supports the hypothesis that the protoribosome further evolved by gene duplication or fusion, with later genetic optimization into two similar but not identical substrates that contribute to the catalytic and decoding properties. Yonath's work provided supporting evidence for the existence of an RNA world where the ribosome co-evolved with its substrate, prior to the contemporary one in which we live.

Ribosomes are common targets of antibiotics. If this site is highly conserved, antibiotics can bind to ribosomes in both bacteria and patients, which can cause death or side effects. Therefore, if an antibiotic targets the conserved PTC region, it is usually harmful, shows resistance and is useful only in treating cancer, and a patient's remaining quality of life is often an issue. Yonath elucidated the modes of action of over twenty different antibiotics that target the ribosome. She illuminated mechanisms of drug resistance and synergism, deciphered the structural basis for antibiotic selectivity and showed that it plays a key role in clinical usefulness and therapeutic effectiveness, thus paving the way for structure-based drug design.

Yonath shares this year's Nobel in Chemistry (http://nobelprize.org/nobel_prizes/chemistry/laureates/2009/)Exit NIEHS with two other scientists, Thomas Steitz, Ph.D., and Venkatraman Ramakrishnan, Ph.D.

(Dixie-Ann Sawin, Ph.D., is a post-doctoral research fellow in the NIEHS Laboratory of Neurobiology Neurotoxicology Group on detail as a writer for the Environmental Factor.)



"Experts Review Revisions..." - previous story Previous story Next story next story - "Oceans Center Study Offers..."
November 2009 Cover Page

Back to top Back to top